Cytek owes Beckman Coulter $56 mln in cell-analysis patent case, US jury says
CTKB•US jury finds Cytek products infringe Beckman patent
A Delaware federal jury determined on Friday that Cytek Biosciences' CTKB.O products for analyzing single-cell blood and tissue samples infringe a patent owned by rival Beckman Coulter.
The jury agreed with Danaher-owned DHR.N Beckman that Cytek's Aurora flow cytometers and other products violate Beckman's patent rights in technology used in its competing CytoFLEX platform.
The jury said that Cytek owed Beckman $36 million in royalties and $20 million in lost profits.
The jury had found on Thursday that Cytek did not infringe two of the three patents at issue in the trial and that those two patents were invalid.
"We are pleased that the jury found in our favor on the substantial majority of claims in this case," Cytek CEO Wenbin Jiang said in a statement. "We fundamentally disagree with the single remaining finding and damages award and intend to pursue all available post-trial remedies, including potentially an appeal."
Spokespeople for Beckman Coulter did not immediately respond to a request for comment on the verdict.
Beckman first sued Cytek over the patents in 2024.
Cytek denied the allegations and argued the patents were invalid.
California-based Cytek earned $201.5 million from overall sales of its products last year, according to a company report.
